|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2004-6-25
|
|
pubmed:abstractText |
Conversion from calcineurin inhibitor (CI)-based maintenance immunosuppression to sirolimus (SRL)-based immunosuppression may be beneficial in selected renal transplant recipients. The purpose of this study was to evaluate the safety and efficacy of a daclizumab (DAC) bridge protocol in patients converted from CI- to SRL-based maintenance immunosuppression.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/daclizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0902-0063
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18 Suppl 12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
61-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15217410-Adult,
pubmed-meshheading:15217410-Aged,
pubmed-meshheading:15217410-Antibodies, Monoclonal,
pubmed-meshheading:15217410-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15217410-Cholesterol,
pubmed-meshheading:15217410-Female,
pubmed-meshheading:15217410-Graft Rejection,
pubmed-meshheading:15217410-Humans,
pubmed-meshheading:15217410-Immunoglobulin G,
pubmed-meshheading:15217410-Immunosuppressive Agents,
pubmed-meshheading:15217410-Kidney Transplantation,
pubmed-meshheading:15217410-Male,
pubmed-meshheading:15217410-Middle Aged,
pubmed-meshheading:15217410-Retrospective Studies,
pubmed-meshheading:15217410-Sirolimus,
pubmed-meshheading:15217410-Triglycerides
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
|
|
pubmed:affiliation |
Department of Pharmacy, Wake Forest University Baptist Medical Center and School of Medicine, Winston-Salem, NC, USA.
|
|
pubmed:publicationType |
Journal Article
|
